* Ensysce Biosciences Inc ENSC.OQ ENSC.O is expected
to show a
fall in quarterly revenue when it reports results on March 21
for the period ending March 31 2024
* The La Jolla California-based company is expected to
report a
68.4% decrease in revenue to $250 thousand from $790 thousand a
year ago, according to the mean estimate from 2 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for Ensysce Biosciences Inc
is for
a loss of 93 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Ensysce
Biosciences Inc is $16.30, above its last closing price
of $0.75.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.87 -1.37 Missed -57.5
Sep. 30 2023 -1.04 -1.06 -0.87 Beat 17.7
Jun. 30 2023 -2.50 -2.73 -0.98 Beat 64.1
Mar. 31 2023 -5.44 -5.08 -2.08 Beat 59
Dec. -30.85 -28.88 -18.24 Beat 36.8
31 2022
Sep. 30 2022 -38.40 -38.40 -8.88 Beat 76.9
Jun. 30 2022 -31.20 -40.80 -57.60 Missed -41.2
Mar. 31 2022 -38.40 -38.40 -14.40 Beat 62.5
This summary was machine generated March 15 at 20:40 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)